Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2021 Net Income-$4.01M-$4.01MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$79,000N/M Operating Incomederived-$949,000N/M Operating Cash Flowderived-$338,000N/M Free Cash Flowderived-$341,000N/M ended Dec 31, 2022 · filed Mar 30, 2023 · 89 d after period end